Effect of dopamine and serotonin receptor antagonists on fencamfamine-induced abolition of latent inhibition  by de Aguiar, Cilene Rejane Ramos Alves et al.
European Journal of Pharmacology 698 (2013) 246–251Contents lists available at SciVerse ScienceDirectEuropean Journal of Pharmacology0014-29
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/ejpharBehavioural pharmacologyEffect of dopamine and serotonin receptor antagonists
on fencamfamine-induced abolition of latent inhibitionCilene Rejane Ramos Alves de Aguiar a,n, Marlison Jose´ Lima de Aguiar b, Roberto DeLucia c,
Maria Teresa Araujo Silva d
a Department of Psychology, Laboratory of Experimental Psychology (LABPEX), CFCH, Federal University of Pernambuco, Recife 50670-901, PE, Brazil
b Department of Psychology, Faculdade Integrada de Vito´ria de Santo Ant ~ao, Vito´ria de Santo Ant ~ao 55610-100, PE, Brazil
c Institute of Biomedical Sciences, University of S ~ao Paulo (USP), S ~ao Paulo 05585-900, SP, Brazil
d Department of Experimental Psychology, Institute of Psychology, University of S ~ao Paulo (USP), S ~ao Paulo 05508-900, SP, Brazila r t i c l e i n f o
Article history:
Received 31 March 2012
Received in revised form
10 October 2012
Accepted 13 October 2012






Attention process99 & 2012 Elsevier B.V.
x.doi.org/10.1016/j.ejphar.2012.10.015
esponding author. Tel.: þ55 81 2126 8730; f
ail address: cilenelabpex@yahoo.com.br (C.R.R
Open access under the Elseva b s t r a c t
The purpose of this investigation was to verify the role of dopamine and serotonin receptors in the
effect of fencamfamine (FCF) on latent inhibition. FCF is a psychomotor stimulant with an indirect
dopaminergic action. Latent inhibition is a model of attention. Latent inhibition is blocked by
dopaminergic agents and facilitated by dopamine receptor agonists. FCF has been shown to abolish
latent inhibition. The serotonergic system may also participate in the neurochemical mediation of
latent inhibition. The selective dopamine D1 receptor antagonist SCH 23390 (7-chloro-3-methyl-1-
phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol), D2 receptor antagonists pimozide (PIM) and methoclo-
pramide (METH), and serotonin 5-HT 2A/C receptor antagonist ritanserin (RIT) were used in the present
study. Latent inhibition was evaluated using a conditioned emotional response procedure. Male Wistar
rats that were water-restricted were subjected to a three-phase procedure: preexposure to a tone, tone-
shock conditioning, and a test of the effect of the tone on licking frequency. All of the drugs were
administered before the preexposure and conditioning phases. The results showed that FCF abolished
latent inhibition, and this effect was clearly antagonized by PIM and METH and moderately attenuated
by SCH 23390. At the doses used in the present study, RIT pretreatment did not affect latent inhibition
and did not eliminate the effect of FCF, suggesting that the FCF-induced abolition of latent inhibition is
not mediated by serotonin 5-HT 2A/C receptors. These results suggest that the effect of FCF on latent
inhibition is predominantly related to dopamine D2 receptors and that dopamine D2 receptors
participate in attention processes.
& 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Fencamfamine (FCF) is a dopaminergic agent whose pharma-
cological and behavioral effects are related to an indirect activa-
tion of dopamine systems in the central nervous system (DeLucia
and Planeta, 1990; DeLucia et al., 1997; Planeta et al., 1995;
Scavone et al., 1985). FCF is characterized by a proﬁle similar to
amphetamine and particularly cocaine. In fact, behavioral studies
have shown that FCF increases locomotion, rearing, and snifﬁng
and provokes anorexia; at high doses, it induces stereotyped
behavior (Aizenstein et al., 1983; Planeta et al., 1989). In vivo
neurochemical studies have shown that the drug increases
dopamine levels in both the caudate-putamen and nucleus
accumbens (Kuczensky et al., 1991), which likely results fromax: þ55 81 2126 8270.
.A. de Aguiar).
ier OA license. the blockade of synaptic dopamine reuptake (Seyfried, 1983).
Evidence indicates that FCF acts as a positive reinforcer. It is
self-administered by monkeys and dogs (Estrada-Robles, 1974;
Risner and Cone, 1986). In rats, it substitutes for cocaine in a drug
discrimination procedure (Risner et al., 1985) and exhibits rein-
forcing properties in place preference conditioning (Planeta et al.,
1995). FCF has been marketed as an antifatigue medication
(Reynolds, 1982) and has been abused by students and athletes
(Delbeke and Debackere, 1981; Gorenstein et al., 1983).
Particularly relevant to the present experiments, FCF abolishes
latent inhibition, as shown in this laboratory (Alves et al., 2002).
Latent inhibition is a behavioral paradigm in which previous
nonreinforced exposure to a stimulus impairs subsequent con-
ditioning to that stimulus (Lubow, 1973; Weiner and Arad, 2009).
Presumably stimuli that do not predict reinforcement are treated
as irrelevant by the organism. As a model of attention, latent
inhibition reﬂects the organism’s ability to learn to ignore
irrelevant stimuli. Latent inhibition is considered a privileged
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because it is reduced in schizophrenia patients (Baruch et al.,
1988; Thornton et al., 1996). It also mimics the difﬁculty that
these patients have been ignoring irrelevant stimuli, and it is
abolished by dopamine receptor agonists and facilitated by
antipsychotic dopamine receptor antagonists in animals and
humans (Aguiar et al., 2011; Alves and Silva, 2001; Alves et al.,
2002; Thornton et al., 1996; Weiner and Arad, 2009; Weiner and
Feldon, 1987). The serotonergic system has also been suggested to
be involved in latent inhibition. Dopaminergic drugs elevate
serotonin levels (Lyon, 1991). Serotonin receptor agonists abolish
latent inhibition (Cassaday et al., 1993; Hitchcock et al., 1997),
and serotonin antagonists facilitate latent inhibition (Alves and
Silva, 2001; Hitchcock et al., 1997).
The aim of the present study was to extend the investigation
of the role of dopaminergic and serotonergic systems in the
abolition of latent inhibition induced by FCF. The dopamine
D2 receptor antagonists pimozide (PIM) and methoclopramide
(METH), the selective dopamine D1 receptor antagonist SCH
23390 (7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benza-
zepin-8-ol), and the serotonin 5-HT2 A/C receptor antagonist
ritanserin (RIT) were tested in the latent inhibition model. Given
the involvement of dopamine and serotonin receptors in latent
inhibition, verifying the eventual predominance of one of these
amines might be an important contribution to understanding
the neurotransmitter systems involved in latent inhibition and
attention.2. Methods
2.1. Animals
The experiments were conducted according to the recommen-
dations of the National Institutes of Health Guide for the Care and
Use of Laboratory Animals. Naive male Wistar rats that weighed
approximately 300 g at the beginning of the experiment were
used. During the ﬁrst week of each experiment, the animals were
housed in groups of ﬁve in 403317 cm polyethylene cages
under a 12 h/12 h reverse light/dark cycle (lights on at 7:00 PM)
and controlled temperature (2171 1C). At the end of that week,
each rat was transferred to individual Inox cages (24.51819 cm).
Food (Purina food pellets) was freely available throughout the
experiment.
2.2. Drugs
The drugs, doses, routes of administration, and pretreatment
intervals followed a protocol routinely used in our laboratory
(Planeta et al., 1995). FCF (Merck), METH (Pharmacotherapy
American Laboratory), SCH 23390 (Sigma-Aldrich), and RIT
(Sigma-Aldrich) were dissolved in a 0.9% NaCl solution (SAL).
PIM (Janssen) was dissolved in a small amount of 1% tartaric acid.
Control solutions were prepared with SAL. FCF, METH, RIT, and
PIM were injected intraperitoneally. SCH 23390 was administered
subcutaneously. SAL was injected by the same route as the drug
with which it was associated. All of the solutions were injected in
a volume of 1 ml/kg.
2.3. Apparatus
Four operant conditioning chambers (322521 cm)
encased in sound-attenuating isolation boxes were used. All of
the equipment was obtained from Med Associates (St. Albans, VT,
USA). A ventilation fan (ENV-025F28) provided background noise.
A removable drinking bottle was located on one wall of the box.Licks were detected by a lickometer circuit (ENV-25 A). Tone
stimuli (10 s, 70 dB, 2.8 kHz) were generated by a Sonalert
module (SC-628). Shock stimuli (0.85 mA, 1 s) were supplied by
a shock generator (ENV-410A) and scrambler (ENV-412) applied
via 0.25 cm diameter stainless steel bars spaced 1.5 cm apart.
A 486-IBM personal computer was programmed to control
stimulus presentation and data acquisition.
2.4. Procedure
The experimental procedure was based on Weiner et al. (1996)
and consisted of four phases conducted during the same AM or
PM period of the day.
2.4.1. Baseline training (days 1–5 )
The animals were individually placed in the experimental
chamber with water available in the lickometer and remained
there for 20 min. Each rat was then returned to its home cage and
allowed to drink for 30 min, after which no water was provided
until the next day.
2.4.2. Preexposure (day 6)
The bottle was removed, and each subject was placed in the
experimental chamber. The preexposed (PE) animals received 40
presentations of a 10 s tone, with an intertrial interval (ITI) of
50 s. The nonpreexposed (NPE) animals were conﬁned to the
chamber for an identical length of time (2400 s), but they did not
receive the tone.
2.4.3. Conditioning (day 7)
Each animal was again placed in the experimental chamber
with the water bottle removed. Five minutes later, the rat was
given two tone-shock pairings spaced 5 min apart. The tone was
identical to the one used during the preexposure phase. Each tone
presentation was immediately followed by a scrambled footshock
(0.85 mA, 1 s). The animals were removed from the box 5 min
after the second shock.
2.4.4. Testing (day 8)
The water bottle was replaced, and each animal was allowed
to drink freely. When the rat had completed 50 licks, the tone was
presented. The tone continued until an additional 25 licks had
been made. If the rat failed to complete these 25 licks within
300 s, then the session was terminated. The suppression ratio was
calculated as the time between licks 50 and 75 (pre-conditioned
stimulus (CS) period) divided by the time between licks 50 and
100 (pre-CS periodþCS period). A complete suppression of
responding would be indicated by a ratio that is close to zero
(i.e., no latent inhibition), whereas a ratio of 0.5 would indicate no
change from the period prior to stimulus presentation (i.e., latent
inhibition). Latent inhibition was deﬁned as a suppression ratio
that was greater in PE than in NPE rats.
2.5. Experimental design
Four experiments were conducted to study the effects of PIM,
METH, SCH 23390, and RIT pretreatment on the FCF-induced
abolition of latent inhibition. Each experimental group was
subdivided into PE and NPE groups. Each of these groups had
corresponding SALþSAL and SALþFCF control groups. These
control groups received an equivalent volume of SAL or FCF
15 min before the experimental session. All of the drugs, with
the exception of SCH 23390, were injected intraperitoneally. SCH
23390 was administered subcutaneously in a volume of 1 ml/kg.
Fig. 1. Effects of PIM and METH pretreatment on the FCF-induced disruption of
latent inhibition. The data are expressed as the mean and standard error of the
suppression ratios (SRs) of PE (preexposed) and NPE (nonpreexposed) groups that
received: (A) 0.9% NaCl solution (SALþSAL), FCF (SALþFCF), PIM (PIMþSAL), and
PIM plus FCF (PIMþFCF) or (B) 0.9% NaCl solution (SALþSAL), FCF (SALþFCF),
METH (METHþSAL), and METH plus FCF (METHþFCF).The number of rats in each
group is shown inside the corresponding bar. 0.5¼no suppression (LI);
0.01¼complete suppression (no LI). *Signiﬁcant difference (Po0.05) between PE
and related NPE group.
C.R.R.A. de Aguiar et al. / European Journal of Pharmacology 698 (2013) 246–2512482.5.1. Pimozide pretreatment
Four groups (SALþSAL, SALþFCF, PIMþSAL, and PIMþFCF)
were subdivided into PE and NPE groups. PIM (1.0 mg/kg) and
FCF (6.0 mg/kg) were administered 4 h and 15 min prior to the
preexposure and conditioning phases, respectively.
2.5.2. Methoclopramide pretreatment
Four groups (SALþSAL, SALþFCF, METHþSAL, and METHþ
FCF) were subdivided into PE and NPE groups. METH (10.0 mg/kg)
and FCF (6.0 mg/kg) were administered 45 and 15 min prior to the
preexposure and conditioning phases, respectively.
2.5.3. SCH 23390 pretreatment
Three SCH 23390 doses were tested (0.01, 0.05, and 0.1 mg/kg).
Four groups (SALþSAL, SALþFCF, SCHþSAL, and SCHþFCF) were
run with each dose. The groups were subdivided into PE and NPE
groups. SCH 23390 and FCF (6.0 mg/kg) were administered 25 and
15 min prior to the preexposure and conditioning phases,
respectively.
2.5.4. Ritanserin pretreatment
Four groups (SALþSAL, SALþFCF, RITþSAL, and RITþFCF)
were subdivided into PE and NPE groups. RIT (0.7 mg/kg) and
FCF (6.0 mg/kg) were administered 20 and 15 min prior to the
preexposure and conditioning phases, respectively.
2.6. Statistical analysis
Suppression ratios were analyzed using a 24 analysis of
variance (ANOVA) with the main factors Preexposure and Drug,
followed by Duncan’s post hoc comparisons between means when
appropriate. In all cases, values of Po0.05 were considered
statistically signiﬁcant.3. Results
3.1. Effect of pimozide pretreatment
Fig. 1A presents the mean suppression ratios in the PIM
(PIMþSAL and PIMþFCF) and saline (SALþSAL and SALþFCF)
groups. As expected when a high level of stimulus preexposure is
used (Aguiar et al., 2011; Alves et al., 2002; Bakshi et al., 1995), a
marked difference was found between the PE and NPE animals in
the SALþSAL group (i.e., a control latent inhibition effect was
clearly observed). In the SALþFCF group, however, a typical effect
of FCF was observed, in which the difference between the PE and
NPE groups was abolished, and no latent inhibition was observed.
When PIMþSAL was administered, the latent inhibition effect
was again present, but a difference was found between the PE and
NPE animals in the PIMþFCF group (i.e., the FCF-induced disrup-
tion of latent inhibition was absent).
The statistical analysis supported this description. The 24
ANOVA revealed signiﬁcant main effects of Preexposure (F1,56¼
178.692, Po0.001) and Drug condition (F1,56¼23.352, Po0.001)
and a signiﬁcant PreexposureDrug condition interaction
(F1,56¼20.666, Po0.001). Duncan’s post hoc comparisons
between means indicated a latent inhibition effect (PE4NPE)
in the SALþSAL, PIMþSAL, and PIMþFCF groups, conﬁrming
that 6.0 mg/kg FCF abolished latent inhibition, and 1.0 mg/kg
PIM blocked this effect.
3.2. Effect of methoclopramide pretreatment
Fig. 1B presents the mean suppression ratios in the
METH (METHþVEH and METHþFCF) and saline (SALþSAL andSALþFCF) groups. A control latent inhibition effect was again
present in the SALþSAL group, and the typical FCF-induced
abolition of latent inhibition was found in the SALþFCF group.
When METHþSAL was administered, the latent inhibition effect
was again observed, but the FCF-induced disruption of latent
inhibition was absent in the METHþFCF group.
The 24 ANOVA revealed signiﬁcant main effects of Preexpo-
sure (F1,64¼116.797, Po0.001) and Drug condition (F1,64¼9.862,
Po0.001) and a signiﬁcant PreexposureDrug condition inter-
action (F1,64¼8.043, Po0.001). Duncan’s post hoc comparisons
between means indicated a latent inhibition effect in the
SALþSAL, METHþSAL, and METHþFCF groups. Thus, the latent
inhibition effect was abolished by 6.0 mg/kg FCF, and 10 mg/kg
METH blocked this effect.3.3. Effect of SCH 23390 pretreatment
Fig. 2 presents the mean suppression ratios in the SCH 23390
(SCHþSAL and SCHþFCF) and saline (SALþSAL and SALþFCF)
groups. Fig. 2A, B, and C show the results from the SCH
23390 groups that received the 0.01, 0.05, and 0.1 mg/kg doses,
respectively. The ﬁgure also shows the results from the FCF
groups that received the same doses. The typical latent inhibi-
tion effect was present in the three SALþSAL groups, and the
typical disruption of latent inhibition by FCF was observed in the
SALþFCF groups. However, when SCHþSAL was administered,
an unexpectedly high suppression ratio was observed, and no
latent inhibition effect was found. In the 0.01 and 0.1 mg/kg
SCHþFCF groups, the FCF-induced abolition of latent inhibition
was unaffected, and the atypical lack of suppression in the
PE and NPE groups was again observed. Only the 0.05 mg/kg
Fig. 2. Effect of SCH 23390 pretreatment on the FCF-induced disruption of latent
inhibition. The data are expressed as the mean and standard error of the
suppression ratios (SRs) of PE (preexposed) and NPE (nonpreexposed) groups
that received 0.9% NaCl solution (SALþSAL), FCF (SALþFCF), SCH 23390
(SCHþSAL), and SCH 23390 plus FCF (SCHþFCF). (A) 0.01 mg/kg SCH 23390.
(B) 0.05 mg/kg SCH 23390. (C) 0.1 mg/kg SCH 23390. The number of rats in each
group is shown inside the corresponding bar. 0.5¼no suppression (LI);
0.01¼complete suppression (no LI). *Signiﬁcant difference (Po0.05) between
PE and related NPE group.
Fig. 3. Effect of RIT pretreatment on the FCF-induced disruption of latent
inhibition. The data are expressed as the mean and standard error of the
suppression ratios (SRs) of PE (preexposed) and NPE (nonpreexposed) groups that
received 0.9% NaCl solution (SALþSAL), FCF (SALþFCF), RIT (RITþSAL), and RIT
plus FCF (RITþFCF). The number of rats in each group is shown inside the
corresponding bar. 0.5¼no suppression (LI); 0.01¼complete suppression (no LI).
*Signiﬁcant difference (Po0.05) between PE and related NPE group.
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of the effect of FCF.
This description was supported by the statistical analysis.
The 24 ANOVA revealed signiﬁcant main effects of Preexposure
(0.01 mg/kg, F1,64¼18.685, Po0.001; 0.05 mg/kg, F1,62¼36.368,
Po0.001; 0.1 mg/kg, F1,64¼9.071, Po0.01) and Drug condition
(0.01 mg/kg, F1,64¼29.833, Po0.001; 0.05 mg/kg, F1,62¼73.253,
Po0.001; 0.1 mg/kg, F1,64¼34.630, Po0.001) and a signiﬁcant
PreexposureDrug condition interaction (0.01 mg/kg,
F1,64¼8.310, Po0.001; 0.05 mg/kg, F1,62¼11.191, Po0.001;
0.1 mg/kg, F1,64¼7.543, Po0.001). Duncan’s post hoc comparisons
between means revealed the typical abolition of latent inhibition
by FCF in the SALþFCF groups and a latent inhibition effect in the
three SALþSAL groups and 0.05 mg/kg SCHþFCF group. The
apparent latent inhibition effect in the 0.01 mg/kg SCHþFCF
group was not conﬁrmed by the post hoc test.3.4. Effect of ritanserin pretreatment
Fig. 3 presents the mean suppression ratios in the RIT
(RITþSAL and RITþFCF) and saline (SALþSAL and SALþFCF)
groups. A marked latent inhibition effect was found in the
SALþSAL control group, and the typical FCF-induced abolition
of latent inhibition was found in the SALþFCF group. When
RITþSAL was administered, the latent inhibition effect was again
present, but the typical FCF-induced disruption of latent inhibi-
tion was absent in the RITþFCF group.
The ANOVA revealed signiﬁcant main effects of Preexposure
(F1,56¼64.404, Po0.001) and Drug condition (F1,56¼14.370,
Po0.001) and a signiﬁcant PreexposureDrug condition inter-
action (F1,56¼19.197, Po0.001). Duncan’s post hoc comparisons
between means indicated a latent inhibition effect in the SAL-
þSAL and RITþSAL groups and blockade of latent inhibition by
6.0 mg/kg FCF. However, the FCF-induced abolition of latent
inhibition found in the SALþFCF group was not affected by RIT
since the latent inhibition scores in the RITþFCF and SALþFCF
groups were not signiﬁcantly different.4. Discussion
The latent inhibition effect (PE4NPE) was found in all of the
saline control groups. FCF consistently reproduced the disruptive
effect of amphetamine on latent inhibition (Aguiar et al., 2011;
Alves et al., 2002; Bakshi et al., 1995; Gray et al., 1992; Killcross
et al., 1994; Moran et al., 1996; Solomon et al., 1981; Warburton
et al., 1994; Weiner and Arad, 2009; Weiner et al., 1988),
suggesting a deﬁcit in selective attention. Two selective dopamine
D2 receptor antagonists were used because of relevant differences
in their mechanism of action. METH has both 5-HT 3 receptor
antagonist action and 5-HT 4 receptor agonist action, which could
affect latent inhibition, learning, and memory (Fontana et al.,
1998; Meneses and Hong, 1997; Moran and Moser, 1992; Terry
et al., 1996). PIM also blocks both dopamine D3 and serotonin
5-HT 2A receptors (Bezchlinyk-Butler and Jeffries, 1997; Freedman
et al., 1994; Griffon et al., 1996; Sokoloff et al., 1992), which have
been implicated in schizophrenia and latent inhibition (Alves and
Silva, 2001; Seeman and Van Tol, 1994). Despite these distinc-
tions, no difference was found in the effect of these two drugs on
latent inhibition. Both substances produced the typical effect of
dopamine D2 receptor antagonists when several preexposure
stimuli presentations were used, in which latent inhibition was
unaffected by these drugs (Ruob et al., 1998; Shadach et al., 1999;
Warburton et al., 1994; Weiner and Arad, 2009). Moreover, both
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inhibition. Thus, the effects observed with these two antagonists
were likely attributable to their antagonism of dopamine D2
receptors, rather than actions on dopamine D3 or serotonin 5-HT 3,
5-HT 4, or 5-HT 2A receptors.
The SCH experiments showed that SCH 23390 was ineffective
at producing latent inhibition, possibly because of the unexpected
increase in the suppression ratio in the three NPE groups. This
peculiar effect of SCH 23390 on latent inhibition was also
reported by Nelson et al. (2012). SCH 23390 pretreatment (0.01
and 0.1 mg/kg) did not antagonize the effect of FCF on latent
inhibition. The effect of FCF on latent inhibition, however, was
slightly but signiﬁcantly blocked by 0.05 mg/kg SCH 23390
pretreatment. Thus, dopamine D1 receptor antagonism by SCH
23390 at this dose mildly reproduced the effects of the dopamine
D2 receptor antagonists PIM and METH on the FCF-induced
abolition of latent inhibition.
At the dosed used in the present study, RIT pretreatment did
not affect latent inhibition. This result is consistent with Cassaday
et al. (1993), who used 0.67 mg/kg and did not observe any effect
of RIT on latent inhibition. Importantly, RIT was not able to block
the FCF-induced abolition of latent inhibition, in contrast to METH
and PIM. This suggests that the FCF-induced abolition of latent
inhibition is not mediated by serotonin 5-HT 2A/C receptors.
Dopamine and serotonin receptor antagonists do not alter
latent inhibition when several preexposure stimuli are presented,
but they facilitate latent inhibition if few such stimuli are given
(Alves and Silva, 2001; Feldon and Weiner, 1991; Weiner and
Arad, 2009; Weiner and Feldon, 1987). In the present study, the
selective dopamine D2 receptor antagonists PIM and METH and
the serotonin 5-HT 2A/C receptor antagonist RIT did not alter latent
inhibition in the saline group. The absence of latent inhibition
deﬁned as PE4NPE in the animals pretreated with the three
doses of the dopamine D1 receptor antagonist SCH 23390 was
attributable to the unexpected increase in the mean suppression
ratio in NPE animals. These animals did not suppress their
responding when the CS was presented. This reduced condition-
ing to the CS in the nonpreexposed groups was also observed
by Nelson et al. (2012) after SCH 23390. Thus, no difference
was observed between preexposed and nonprexposed groups
that received SCH 23390, but this atypical disruption of latent
inhibition is qualitatively different from the disruption produced
by FCF, as Nelson et al. (2012) have noticed in relation to
amphetamine.
Some possible reasons for this ﬁnding are the following. Motor
behavior is a relevant variable to consider because previous
studies have shown that systemically administered SCH 23390
reduced locomotion in rats (e.g., Hoffman and Beninger (1985),
Meyer et al. (1993)). However, although motor behavior was not
directly assessed, a suppression ratio close to 0.5 in animals that
received SCH 23390 indicates that they were able to move and
lick the water. A possible explanation for the failure of suppres-
sion in the nonpreexposed animals that received SCH 23390 could
be a change in pain threshold as a result of drug administration.
A reduction of the aversive properties of the unconditioned
stimulus (US) by administering the dopamine D1 antagonist,
however, was not observed in our laboratory using a hot plate
procedure (unpublished observations) or in other studies that
measured shock reactivity (Greba and Kokkinidis, 2000) and
shock-induced vocalization (Inoue et al., 2000). Another hypoth-
esis is that SCH 23390 interfered with Pavlovian conditioning.
Interference of SCH 23390 with appetitive Pavlovian conditioning
has been demonstrated (e.g., Eyny and Horvitz (2003)). SCH
23390 has also been shown to block the acquisition of fear-
potentiated startle (Greba and Kokkinidis, 2000) and reduce
conditioned fear, reﬂected by freezing behavior (Inoue et al.,2000). In the present study, the drug may have interfered with
learning the CS–US association, so the conditioned fear response
expressed as licking suppression was not observed. Another
reasonable hypothesis for the deﬁcient suppression observed
could be the interference of SCH 23390 on memory retention,
hindering retrieval of the association that was learned during the
conditioning phase. Although working and reference memory do
not appear to be affected by systemic SCH 23390 treatment in rats
(Bushnell and Levin, 1993), other studies point to mnemonic
impairment caused by dopamine D1 receptor antagonism.
Arnsten et al. (1994) showed that systemic SCH 23390 adminis-
tration impaired memory performance in young monkeys in a
delayed response task, whereas agonist-induced improvements
were blocked by this drug. The deleterious effects of SCH 23390
on both spatial and nonspatial memory formation in rats have
been reported (Clausen et al., 2011). Local central injections of
SCH 23390 reproduce the memory impairment observed after
systemic administration. Microinjection of SCH 23390 into the
nucleus accumbens eliminated short-term memory formation
(Fenu et al., 2001), and SCH 23390 administration into the CA1
area of the dorsal hippocampus caused retrograde amnesia
(Vianna et al., 2001). Administration of SCH 23390 into the medial
frontal cortex impaired the sharpness of attention and blocked
the memory improvement produced by the dopamine D1 receptor
agonist SKF 38393 (Granon et al., 2000).
Because SCH 23390 did not produce latent inhibition at any of
the doses tested, a dose-response effect was not obtained,
perhaps because an effective dose range was not used. More
likely, however, is that the lack of an SCH 23390 dose-response
effect in the present experiments is attributable to a ceiling effect
observed in the responding of nonpreexposed animals during CS
presentations.
The weakness of the SCH 23390 effect on the FCF-induced
abolition of latent inhibition is consistent with previous results,
in which the selective dopamine D1 receptor antagonists NCC
01-01112 and SCH 39166 did not affect latent inhibition (Trimble
et al., 2002) and dopamine D1 receptor agonist SKF 38393 had no
inﬂuence on the formation of latent inhibition (Loskutova et al.,
2010). The results are also consistent with the poor clinical response
to D1 receptor antagonists (Trimble et al., 2002; Wiesel et al., 1990).5. Conclusions
The use of dopamine and serotonin receptor antagonists has
been a successful strategy aimed at elucidating the participation
of these neurotransmitters in the effect of FCF on latent inhibition.
The selective dopamine D2 receptor antagonists PIM and METH
blocked the effect of FCF on latent inhibition. The selective
dopamine D1 receptor antagonist SCH 23390 had a moderate
effect in the same direction but only at one of the doses tested.
The serotonin 5-HT 2A/C receptor antagonist RIT was ineffective in
this regard. Thus, both the dopamine D1 and D2 receptor subtypes
appear to mediate the FCF-induced abolition of latent inhibition,
but clearly such an effect is mainly attributable to the drug’s
action on D2 receptors. The present study further supports the
hypothesis that dopamine D2 receptor transmission is the pre-
dominant basis of latent inhibition and the therapeutic action of
antipsychotics on attention.Acknowledgments
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